Detalhe da pesquisa
1.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891379
2.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891380
3.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Br J Dermatol
; 188(1): 22-31, 2023 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36689515
4.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol
; 188(3): 330-340, 2023 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36751950
5.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36967713
6.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182701
7.
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Lancet
; 397(10273): 475-486, 2021 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549192
8.
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Lancet
; 397(10273): 487-498, 2021 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33549193
9.
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
Dermatol Ther (Heidelb)
; 13(3): 751-768, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36648594
10.
Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials.
J Clin Oncol
; 21(15): 2982-92, 2003 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12885819